Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
©2024 American Association for Cancer Research..
SUMMARY: While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit-risk assessment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Blood cancer discovery - (2024) vom: 04. März, Seite OF1-OF7 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1158/2643-3230.BCD-24-0022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369311035 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369311035 | ||
| 003 | DE-627 | ||
| 005 | 20240305233230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2643-3230.BCD-24-0022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM369311035 | ||
| 035 | |a (NLM)38441243 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghobrial, Irene M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a ©2024 American Association for Cancer Research. | ||
| 520 | |a SUMMARY: While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit-risk assessment | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Gormley, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 700 | 1 | |a Mateos, Maria-Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Bergsagel, P Leif |e verfasserin |4 aut | |
| 700 | 1 | |a Chesi, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Dhodapkar, Madhav V |e verfasserin |4 aut | |
| 700 | 1 | |a Dispenzieri, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Kastritis, Efstathios |e verfasserin |4 aut | |
| 700 | 1 | |a Kristinsson, Sigurdur Y |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Climent, Jose Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Manier, Salomon |e verfasserin |4 aut | |
| 700 | 1 | |a Marinac, Catherine R |e verfasserin |4 aut | |
| 700 | 1 | |a Maura, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, Gareth J |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Faith E |e verfasserin |4 aut | |
| 700 | 1 | |a Nadeem, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Nuvolone, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Prosper, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi A |e verfasserin |4 aut | |
| 700 | 1 | |a Sklavenitis-Pistofidis, Romanos |e verfasserin |4 aut | |
| 700 | 1 | |a Sperling, Adam S |e verfasserin |4 aut | |
| 700 | 1 | |a Vassiliou, George S |e verfasserin |4 aut | |
| 700 | 1 | |a Munshi, Nikhil C |e verfasserin |4 aut | |
| 700 | 1 | |a Castle, Philip E |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Kenneth C |e verfasserin |4 aut | |
| 700 | 1 | |a San Miguel, Jesus F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer discovery |d 2020 |g (2024) vom: 04. März, Seite OF1-OF7 |w (DE-627)NLM31368555X |x 2643-3249 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:03 |g pages:OF1-OF7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2643-3230.BCD-24-0022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 03 |h OF1-OF7 | ||